A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke

Chronic Ischemic Stroke Clinical Trial

Official title: A Phase 1 Dose-escalation, Single-Center, Open-labeled Study to Evaluate the Safety and Tolerability of Human Induced Pluripotent Stem Cell-derived Human Forebrain Neural Progenitor Cell Injection (hNPC01) in Chronic Ischemic Stroke

Status Recruiting

Clinical Trial Summary

The principal aims of the clinical investigation involve assessing the safety profile and MTD of human forebrain neural progenitor cells (hNPC01) administered at escalated doses via single-dose intracerebral injection to subjects with stable chronic ischemic stroke.

Clinical Trial Description

The primary aims of this open-label single-armed study is to evaluate the safety and tolerability up to 4 cohorts of escalating doses of hNPC01 administered at a single dose via intracerebral injection to subjects with chronic cerebral ischemic stroke, and to determine MTD. The exploratory aim is to explore the evaluation tools with preliminary efficacy assessment and the potential of hNPC01 to mitigate the symptoms, especially motor symptoms associated with chronic stroke. Eligible participants for this study are individuals who have experienced a single ischemic stroke 6 to 60 months prior of enrollment and have exhibited no significant improvement following standard physical therapy interventions. ;

Related Conditions & MeSH terms

• Cerebral Infarction
• Chronic Ischemic Stroke
• Ischemia
• Ischemic Stroke
• Stroke

• NCT number: NCT06299033
• Study type: Interventional
• Source: Hopstem Biotechnology Inc.
• Contact: Shuning Zhang, Ph.D
• Phone: +86 571-88197776
• Email: shuningzh@hopstem.com
• Status: Recruiting
• Phase: Phase 1
• Start date: November 9, 2023
• Completion date: December 30, 2025